Paul Tudor Jones's HAE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 45,776 shares of Haemonetics Corporation (HAE) worth $3.67 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in HAE, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 45,776 shares. Largest reduction occurred in Q3 2018, reducing 28,066 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +45,776 | New Buy | 45,776 | $80.15 |
| Q2 2025 | -19,598 | Sold Out | 0 | $0.00 |
| Q1 2025 | +19,598 | New Buy | 19,598 | $63.55 |
| Q4 2024 | -3,065 | Sold Out | 0 | $0.00 |
| Q3 2024 | +3,065 | New Buy | 3,065 | $80.38 |
| Q2 2023 | -16,353 | Sold Out | 0 | $0.00 |
| Q1 2023 | +16,353 | New Buy | 16,353 | $0.08 |
| Q1 2020 | -6,886 | Sold Out | 0 | $0.00 |
| Q4 2019 | +3,576 | Add 108.04% | 6,886 | $114.87 |
| Q3 2019 | +3,310 | New Buy | 3,310 | $126.28 |
| Q2 2019 | -27,729 | Sold Out | 0 | $0.00 |
| Q1 2019 | +14,886 | Add 115.91% | 27,729 | $87.49 |
| Q4 2018 | +6,206 | Add 93.51% | 12,843 | $100.05 |
| Q3 2018 | -28,066 | Reduce 80.87% | 6,637 | $114.51 |
| Q2 2018 | +18,456 | Add 113.60% | 34,703 | $89.68 |
| Q1 2018 | +2,210 | Add 15.74% | 16,247 | $73.18 |
| Q4 2017 | -8,622 | Reduce 38.05% | 14,037 | $58.06 |
| Q3 2017 | -5,467 | Reduce 19.44% | 22,659 | $44.88 |
| Q2 2017 | +143 | Add 0.51% | 28,126 | $39.50 |
| Q1 2017 | +15,737 | Add 128.51% | 27,983 | $40.56 |
| Q4 2016 | +12,246 | New Buy | 12,246 | $40.18 |
| Q3 2016 | -16,898 | Sold Out | 0 | $0.00 |
| Q2 2016 | +16,898 | New Buy | 16,898 | $29.00 |
| Q3 2014 | -10,100 | Sold Out | 0 | $0.00 |
| Q2 2014 | -19,418 | Reduce 65.78% | 10,100 | $35.25 |
| Q1 2014 | +23,618 | Add 400.31% | 29,518 | $32.59 |
| Q4 2013 | -2,800 | Reduce 32.18% | 5,900 | $42.20 |
| Q3 2013 | -1,100 | Reduce 11.22% | 8,700 | $39.89 |
| Q2 2013 | +9,801 | Add 0.00% | 9,800 | $41.33 |
Paul Tudor Jones's Haemonetics Corporation Investment FAQs
Paul Tudor Jones first purchased Haemonetics Corporation (HAE) in Q2 2013, acquiring 9,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Haemonetics Corporation (HAE) for 29 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Haemonetics Corporation (HAE) was in Q4 2025, adding 45,776 shares worth $3.67 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 45,776 shares of Haemonetics Corporation (HAE), valued at approximately $3.67 M.
As of the Q4 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Haemonetics Corporation (HAE) was 45,776 shares, as reported at the end of Q4 2025.